Key result
Among patients with severe mitral regurgitation ineligible for intervention, one-year all-cause mortality did not differ between the two identified phenogroups (21.4% vs 23.4%, P=0.89).
Why the study?
A significant proportion of patients with severe mitral regurgitation remain ineligible for any mitral valve intervention, and their phenotypic characteristics are not well defined.
What are the phenotypic characteristics and 1-year mortality of patients with severe mitral regurgitation who are ineligible for mitral valve interventions?
Cohort (n=284)
Yes
What are the phenotypic characteristics and 1-year mortality of patients with severe mitral regurgitation who are ineligible for mitral valve interventions?
Patients with severe mitral regurgitation ineligible for interventions fall into two distinct phenotypes (elderly women with primary MR/annular calcification vs. secondary MR with advanced HF) with similarly high 1-year mortality (~22%).
AIMS: Although several treatment options are available for patients with severe mitral regurgitation (MR), a significant proportion of patients remain ineligible for any mitral valve (MV) intervention. We aimed to analyse the phenotypic characteristics of surgical high-risk patients ineligible for MV interventions using an unsupervised phenotypic clustering approach. METHODS AND RESULTS: Between 2014 and 2022, the CHOICE-MI registry included 984 patients with MR undergoing screening for transcatheter MV replacement at 33 international sites. For this study, only patients with screening failure receiving medical therapy alone were included. Patients receiving transcatheter or surgical treatment were excluded. A cluster analysis using K-means was performed on baseline clinical, demographic, and imaging variables to identify different patient phenotypes. Among 284 patients with MR (77.4 ± 8.82 years, 56.0% female, EuroSCORE II: 6.6 ± 5.8%) considered ineligible for any MV intervention, two clinically distinct phenogroups (PGs) were identified using unsupervised hierarchical clustering of principal components: PG1, elderly women with primary MR, preserved left ventricular function, and annular calcification; and PG2, patients with secondary MR, advanced heart failure, and high prevalence of comorbidities. One-year all-cause mortality did not differ between the PGs (PG1: 21.4%, PG2: 23.4%, P = 0.89). Predictors of mortality were albumin, renal function, and extracardiac arteriopathy for PG1 and albumin, coronary artery disease, and prior myocardial infarction for PG2. CONCLUSION: This study identified two major subgroups among patients ineligible for mitral interventions showing profound differences in clinical and anatomical profiles. Identifying these factors may drive technological evolution to address the unmet clinical need for therapeutic options in MR patients. CLINICALTRIALS.GOV IDENTIFIER: NCT04688190 (CHOICE-MI Registry).
No takes yet. Share an insight, caveat, or question.
Ludwig et al. (2025) conducted a cohort in Severe mitral regurgitation ineligible for intervention (n=284). Phenogroup 1 (primary MR, preserved LV function, annular calcification) vs. Phenogroup 2 (secondary MR, advanced heart failure, comorbidities) was evaluated on One-year all-cause mortality (p=0.89). Among patients with severe mitral regurgitation ineligible for intervention, one-year all-cause mortality did not differ between the two identified phenogroups (21.4% vs 23.4%, P=0.89).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: